A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Daridorexant (QUVIVIQ)

Orexin Receptor Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2022-04-07
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$36.5M in CY2024 Part D spend69K claims · 21K beneficiaries · 329 plans surveyed

Lowest NADAC
$16.70/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$16.71
Across all dosage forms in distribution.
Highest NADAC
$16.73
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Daridorexant used for?

Daridorexant is a Orexin Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Daridorexant?

No. Daridorexant is brand-only with no generic equivalents currently in market.

How much does my plan pay for Daridorexant?

Across 329 Part D plans, Daridorexant averages $16.71/unit (NADAC). Lowest available: $16.70/unit. Highest in distribution: $16.73/unit.

Is Daridorexant on the FDA shortage list?

No. Daridorexant is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Orexin Receptor Antagonist2 alternatives in D1
01
Lemborexant
Brand: DAYVIGO
$11.57Lowest NADAC
0Generic mfrs
$32.5MCY24 Part D spend
Compare →
02
Suvorexant
Brand: BELSOMRA
$15.22Lowest NADAC
0Generic mfrs
$222.6MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.